Bladder Cancer

Scope & Guideline

Exploring innovative treatments for bladder cancer.

Introduction

Explore the comprehensive scope of Bladder Cancer through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Bladder Cancer in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2352-3727
PublisherIOS PRESS
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2015 to 2024
AbbreviationBLADDER CANCER / Bladder Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS

Aims and Scopes

The journal 'Bladder Cancer' focuses on advancing the understanding, diagnosis, treatment, and management of bladder cancer through rigorous research and clinical studies. It encompasses a broad range of topics that contribute to the field of urologic oncology.
  1. Clinical Research and Trials:
    The journal emphasizes clinical trials, including novel therapies, surgical techniques, and chemotherapy regimens, to provide evidence-based practices for treating bladder cancer.
  2. Biomarkers and Molecular Studies:
    Research on molecular subtypes, biomarkers, and genetic factors plays a crucial role in understanding bladder cancer pathogenesis and tailoring individualized therapies.
  3. Patient-Centered Approaches:
    The journal highlights studies focusing on patient decision-making, quality of life, and supportive care, recognizing the importance of patient experiences and preferences in treatment outcomes.
  4. Innovative Treatment Modalities:
    Exploration of new treatment strategies, including immunotherapy, targeted therapy, and advanced surgical techniques, reflects the journal's commitment to improving therapeutic options for bladder cancer patients.
  5. Epidemiology and Risk Factors:
    Investigations into the epidemiology, risk factors, and preventive measures related to bladder cancer are integral to understanding disease trends and improving public health initiatives.
The field of bladder cancer research is dynamic, with several emerging themes that have gained traction in recent publications. These trends indicate a shift towards more innovative and patient-focused approaches.
  1. Immunotherapy and Novel Therapeutics:
    A significant increase in studies focusing on immunotherapy, including checkpoint inhibitors and antibody-drug conjugates, highlights a trend towards utilizing the immune system to combat bladder cancer.
  2. Patient Quality of Life and Psychosocial Factors:
    Research exploring the quality of life, psychosocial impacts, and supportive care for bladder cancer patients is on the rise, emphasizing the importance of holistic approaches to treatment.
  3. Integration of Biomarkers in Clinical Practice:
    There is a growing trend towards integrating biomarker studies in clinical settings, enabling personalized medicine approaches that tailor treatments based on individual patient profiles.
  4. Real-World Evidence and Patient-Centric Research:
    Studies utilizing real-world data to assess treatment outcomes and patient experiences are increasingly prominent, reflecting a shift towards understanding the practical implications of treatment in diverse populations.
  5. Management of Non-Muscle Invasive Bladder Cancer (NMIBC):
    An emerging focus on the management strategies for NMIBC, including surveillance protocols and treatment innovations, indicates a need for more effective approaches in this prevalent disease category.

Declining or Waning

While the journal continues to thrive in many areas, certain themes have shown a decline in prominence over recent years. This may reflect shifting research priorities or advancements in other areas.
  1. Basic Science and Animal Studies:
    There has been a noticeable reduction in the publication of basic science and animal model studies, as the focus shifts towards clinical applications and human studies that directly impact patient care.
  2. Historical and Epidemiological Analyses:
    Research articles examining historical data or long-term epidemiological trends have become less frequent, possibly indicating a move towards more immediate clinical relevance and actionable findings.
  3. Traditional Chemotherapy Studies:
    The emphasis on traditional chemotherapy regimens has waned as newer therapies, particularly immunotherapies and targeted agents, gain traction in clinical practice, reflecting the evolving landscape of cancer treatment.

Similar Journals

Actas Urologicas Espanolas

Exploring Breakthroughs in Urological Medicine
Publisher: ELSEVIER ESPANAISSN: 0210-4806Frequency: 10 issues/year

Actas Urologicas Espanolas is a prestigious journal published by Elsevier España, dedicated to the field of Urology. Established in 1977, this journal has significantly contributed to advancing knowledge and research in urological medicine and surgery, spanning a comprehensive scope that includes clinical studies, surgical techniques, and the latest innovations in the treatment of urological diseases. With an impact factor reflecting its critical role in the academic community, it is ranked Q3 in the Urology category as of 2023, placing it amongst the valuable resources for professionals and researchers. The journal is indexed under Scopus, achieving a commendable rank of #70 out of 120 in the Medicine-Urology category, situating it within the 42nd percentile. As a significant platform for sharing advancements and findings, it encourages submissions that enhance urological care and improve patient outcomes. Although not an Open Access journal, the publication remains vital for those looking to stay updated on the latest developments in urology. For more details, visit their office located at CALLE DE ZURBANO, 76-4TH FLR LEFT, MADRID, 28010, SPAIN.

Oncology Reviews

Advancing the Frontier of Cancer Research
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

Advances in Urology

Elevating Standards in Urological Care and Research
Publisher: HINDAWI LTDISSN: 1687-6369Frequency: 1 issue/year

Advances in Urology is a premier scholarly journal published by HINDAWI LTD that has been contributing to the field of urology and obstetrics since its establishment. With an impact factor reflecting its growing influence, this Open Access journal, available since 2008, ensures that researchers and professionals can readily access cutting-edge developments in urological health, surgical techniques, and innovative treatment methodologies. Based in the United States, the journal covers a wide array of topics relevant to urology and obstetrics, maintaining a notable presence in academic rankings, with a Q2 category designation in both fields as of 2023. The journal is indexed in Scopus, ranking #54 out of 120 in Urology and #95 out of 209 in Obstetrics and Gynecology, further adding to its credibility and reach. As it converges from 2009 to 2024, Advances in Urology continues to be a vital resource for researchers, professionals, and students seeking to stay abreast of significant advancements and discussions within these critical areas of medicine.

African Journal of Urology

Fostering Collaboration for Healthier Futures
Publisher: SPRINGERISSN: 1110-5704Frequency: 1 issue/year

African Journal of Urology (ISSN: 1110-5704, E-ISSN: 1961-9987) is a leading scholarly publication in the field of urology, published by SPRINGER from the United Kingdom. Since adopting an open access model in 2012, this journal has aimed to increase the visibility and dissemination of vital research findings across the African continent and beyond. With a current impact factor and significant standing, as denoted by its Q3 ranking in Urology for 2023, it serves as an essential platform for clinicians, researchers, and students alike. The journal's scope encapsulates all aspects of urology, fostering advancements in both clinical practices and innovative research while specifically addressing healthcare challenges relevant to African populations. As part of its commitment to accessibility and academic excellence, the journal offers full open access to its content, allowing for a broad readership and engagement with cutting-edge studies. Engage with the African Journal of Urology to contribute to and stay informed about vital developments in urological science.

BREAST

Advancing breast health through cutting-edge research.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Indian Journal of Urology

Your Gateway to Cutting-Edge Urological Research.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0970-1591Frequency: 4 issues/year

Indian Journal of Urology, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to the field of urology, serving as a vital platform for researchers and clinicians to disseminate groundbreaking findings since its inception in 2001. With an ISSN of 0970-1591 and an E-ISSN of 1998-3824, this journal has established itself as a crucial resource for advancing knowledge in urological practices, particularly within the Indian context. Recognized in the 2023 Scopus Rankings with a classification of Q3 in Urology, it stands at a significant position (Rank #71 out of 120) with a 41st percentile performance, highlighting its role in contributing to the global discourse in urological medicine. The journal provides open access options, ensuring that high-quality research is readily available to a broad audience, fostering collaboration and innovation. Publishing significant studies from various converged years, including from 1984 to 1999 and more recently from 2006 to 2024, Indian Journal of Urology is essential for professionals seeking to stay updated with the latest advances and best practices in urology.

Current Urology

Innovative Insights in Urology, Oncology, and Reproductive Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1661-7649Frequency: 4 issues/year

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Journal of Thoracic Oncology

Exploring Breakthroughs in Lung Cancer Treatment
Publisher: ELSEVIER SCIENCE INCISSN: 1556-0864Frequency: 12 issues/year

Journal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.

Cancer Management and Research

Advancing oncology through innovative research.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1322Frequency: 1 issue/year

Cancer Management and Research, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to advancing the field of oncology. Since its inception in 2009, this journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals focused on cancer treatment and management. With its robust impact factor and impressive Scopus ranking in the 77th percentile of oncology medicine, it provides a prominent platform for sharing high-quality research. The journal covers a wide range of topics within cancer management, including innovative therapeutic strategies, clinical trials, patient care, and health policy, ensuring a comprehensive approach to current challenges in the field. Operating from New Zealand, it invites contributions that can shape the future of oncology and improve patient outcomes globally, making it an essential addition to the libraries of those engaged in cancer research and practice.

Clinical Lymphoma Myeloma & Leukemia

Pioneering Insights into Lymphoma, Myeloma, and Leukemia
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.